Omeros (OMER)
(Delayed Data from NSDQ)
$4.87 USD
-0.15 (-2.99%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $4.85 -0.02 (-0.41%) 6:54 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Brokerage Reports
0 items in cart
Omeros Corporation [OMER]
Reports for Purchase
Showing records 21 - 40 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
FDA Accepts Narsoplimab Application With Priority Review; Raising PT to $34
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
OMIDRIA Sales Likely to Decline Near-Term; Modulating PT to $31
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Q4:20 & CY21: OMIDRIA - Qualifies for Separate Payment in the ASCs
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Narsoplimab Regulatory Submission Complete; 3Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Q3: Completion of Narsoplimab/HSCT-TMA BLA Submission Anticipated Imminently
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Narsoplimab Efficacy Data Ready For Submission; Preclinical Look at OMS906/PNH
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Narsoplimab Pivotal Trial Final Efficacy Data Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
OMS906 Cleared to Enter Clinical Testing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Q2: Narsoplimab Progress; OMIDRIA Sales Likely Drop in Oct; OMS906/PNH into P1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Dual Financing Transactions; 2Q20 Financial Results; Lowering PT to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
1Q20 Financials; OMIDRIA Sales Impacted by Pandemic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Omeros Corporation
Industry: Medical - Products
COVID-19 Likely to Impact OMIDRIA Sales Into Potential Passthrough Expiry 9/30
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L